Specifically, the Company received U.S. Patent No. 9,265,656 entitled "Grid Pattern Laser Treatment and Methods for Treating an Eye" and U.S. Patent No. 9,278,029 entitled "Short Duration Pulse Grid Pattern Laser Treatment and Methods." Expanding on the core MicroPulse technology, these new patents cover automatic laser delivery with multi-spot pattern scanning for efficient retinal photocoagulation that is tissue sparing and enables faster treatment procedures.
"Physicians continue to report high satisfaction with the TxCell Scanning Laser Delivery Systems, noting that they are able to safely and effectively treat their patients without the risks and complexities of conventional products or invasive implant technologies," said President and CEO
"The successful adoption rate and rapid growth of MicroPulse, for use in both retinal and more recently glaucoma procedures, has brought new attention to the Company and our market. In response, we have a series of additional patent applications pending in the U.S. and
About
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the Company's patents and other intellectual property rights, the Company's patent applications and the issuance of any patents to the Company based upon such applications, the relevance of the Company's patents and other intellectual property rights to the Company's current and future product portfolio, the protectability of, and results of any future challenges to, the Company's intellectual property rights, the Company's products, including the TxCell™ Scanning Laser Delivery System and MicroPulse® technology, future demand and order levels for the Company's products, the adoption and effect of Company products on its results, the markets in which the Company operates, usage and efficacy of the Company's products, future financial results, and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/iridex-gains-patent-approvals-covering-txcell-guided-micropulse-laser-therapy-predictably-enables-faster-durable-treatments-for-glaucoma-and-retinal-diseases-300239775.html
SOURCE
Company Contact: Will Moore, President & Chief Executive Officer, 650-940-4700; or Investor Relations Contact: Matt Clawson, Pure Communications, 949-370-8500, matt@purecommunicationsinc.com